AIDS reviews最新文献_第2页

HIV infection and esophageal cancer in Sub-Saharan Africa: a comprehensive meta-analysis. 撒哈拉以南非洲地区的艾滋病毒感染与食道癌：一项综合荟萃分析。

IF 1.9 4区医学

AIDS reviews Pub Date : 2024-01-01 DOI: 10.24875/AIDSRev.23000018

Gabriel Kamsu-Tchuente, Eugene J Ndebia

{"title":"HIV infection and esophageal cancer in Sub-Saharan Africa: a comprehensive meta-analysis.","authors":"Gabriel Kamsu-Tchuente, Eugene J Ndebia","doi":"10.24875/AIDSRev.23000018","DOIUrl":"10.24875/AIDSRev.23000018","url":null,"abstract":"Africa hosts the highest burden of esophageal cancer (49%) and HIV (60%) worldwide. It is imperative to investigate the synergistic impact of these two diseases on African populations. This study conducted an exhaustive computerized search of databases, including Medline/PubMed, Embase, Web of Science, Scopus, Cochrane library, and African Journals Online, to identify eligible studies up to October 2023. HIV infection was the exposure, esophageal cancer risk was the outcome, and healthy subjects with no cancer history served as comparators. Study quality was assessed using the Newcastle-Ottawa scale, and potential publication bias was evaluated through funnel plots and the Egger test. Meta-analyses were conducted using Stata 17.0 software and involved a thorough examination of 98,397 studies. Out of these, eight studies originating from Eastern and Southern Africa, recognized as esophageal cancer hotspots on the continent, met the eligibility criteria. The analysis revealed a non-significant association between HIV infection and esophageal cancer risk (odds ratio = 1.34 [95% confidence interval, 0.85-2.12]; with 0.26 as p-value of overall effects). The Egger test yielded a p-value of 0.2413, suggesting the absence of publication bias. In summary, this systematic review and meta-analysis indicate that there is no established causal link between HIV infection and esophageal cancer risk. However, further research is essential to delve into the potential mechanisms underlying this relationship.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140292516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis. 艾滋病毒感染者中 COVID-19 的风险因素和死亡结果：系统回顾和荟萃分析。

IF 2.2 4区医学

AIDS reviews Pub Date : 2024-01-01 DOI: 10.24875/AIDSRev.23000017

Mahmoud Kandeel

{"title":"Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis.","authors":"Mahmoud Kandeel","doi":"10.24875/AIDSRev.23000017","DOIUrl":"10.24875/AIDSRev.23000017","url":null,"abstract":"This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients. Patients aged ≥ 60 years (hazard ratio [HR] = 2.22; 95% CI: 1.617, 3.050; p < 0.001), male (HR = 1.668; 95% CI: 1.179, 2.361; p = 0.004), and people with diabetes (risk ratio [RR] = 3.34; 95% CI: 1.45, 7.68; p = 0.005) were at higher risk of death. Adherence to antiretroviral therapy (ART) reduced mortality risk (RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02). Patients in the survival groups showed a statistically significant lower mean of C-reactive protein (mean difference = 114.08; 95% -74.05, 154.10; p < 0.001). Deceased patients showed higher mean levels of interleukin-6 (IL-6). Chronic respiratory disorders, hypertension, oxygen requirement, admission to an intensive care unit, D-dimer levels, and HIV viral load < 50 copies RNA/mL before admission did not show statistically significant differences between the deceased and survival groups. ART therapy reduced mortality risk (RR = 0.90; 95% 0.83, 0.98; p = 0.02). Identifying PLHIV at higher mortality risk could improve the outcomes of COVID-19 by stratifying these patients to the most effective treatment in a timely fashion.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140292519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HTLV in Sweden. 瑞典的 HTLV。

IF 2.2 4区医学

AIDS reviews Pub Date : 2024-01-01 DOI: 10.24875/AIDSRev.24000002

Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak

引用次数: 0

HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. 整合酶抑制剂比特拉韦、卡博替拉韦和多罗替拉韦治疗的HIV-1耐药性和病毒学失败：系统性文献综述。

IF 1.9 4区医学

AIDS reviews Pub Date : 2024-01-01 DOI: 10.24875/AIDSRev.24000011

Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés

{"title":"HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.","authors":"Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés","doi":"10.24875/AIDSRev.24000011","DOIUrl":"https://doi.org/10.24875/AIDSRev.24000011","url":null,"abstract":"We describe and analyze resistance-associated mutations (RM) and virological failures (VF) on antiretroviral therapy using the latest approved integrase inhibitors (INIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB), together with their companion drugs in fixed-dose formulations: BIC/emtricitabine/tenofovir; CAB/rilpivirine; DTG/abacavir/lamivudine; DTG/emtricitabine/tenofovir; and DTG/lamivudine. Systematic literature searches were conducted in PubMed and other electronic databases for clinical studies published between January 2010 and May 2023, according to preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA), which analyzed VFs and RMs of INIs. Fifty clinical studies were included in the synthesis. VF in antiretroviral treatment (ART)-naïve patients occurred in 0.7-4.0%, 0.6-1.4%, and 0.6-9.0% of patients treated with DTG, BIC, and CAB, respectively. VF was reported in patients with previous ART in 0-8.1%, 0-2.0%, and 0.4-2.3% of those treated with DTG, BIC, and CAB, respectively. RMs were detected in ART-naïve patients in only one study with DTG (0.3%), none of the studies with BIC, and three of the studies with CAB (0.1-5.4%). In ART-experienced patients, RMs were detected in 0-1.9% of DTG-treated patients. No cases of RM were detected in the 11 BIC studies reviewed. In the case of CAB, RMs were detected in eight studies, ranging from 0.3% to 1.9% of patients. In conclusion, RM rates in the studies reviewed were generally low using the latest INIs. This review identified BIC as the INI with the lowest number of observed VF and lack of RM.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals. 非艾滋病毒病毒感染的暴露前预防和长效抗病毒药物的作用。

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-12-15 DOI: 10.24875/AIDSRev.M23000066

Vicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, José V Fernández-Montero, Ana Treviño, Octavio Corral, Fernando de Jesús, Pablo Barreiro

{"title":"Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals.","authors":"Vicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, José V Fernández-Montero, Ana Treviño, Octavio Corral, Fernando de Jesús, Pablo Barreiro","doi":"10.24875/AIDSRev.M23000066","DOIUrl":"10.24875/AIDSRev.M23000066","url":null,"abstract":"Viruses cause a large burden of human infectious diseases. During the past 50 years, antivirals have been developed to treat many pathogenic viruses, including herpesviruses, retroviruses, hepatitis viruses, and influenza. Besides being used as treatment, antivirals have shown efficacy for preventing certain viral infections. Following the success in the HIV field, a renewed interest has emerged on the use of antivirals as prophylaxis for other viruses. The development of formulations with extended half-life has pushed further this consideration in persons at risk for a wide range of viral infections. In this way, long-acting antivirals might behave as \"chemovaccines\" when classical vaccines do not exist, cannot be recommended, immune responses are suboptimal, escape mutants emerge, and/or immunity wanes. Five main caveats would temper its use, namely, selection of drug resistance, drug interactions, short- and long-term side effects, potential teratogenicity in women of child-bearing age, and high cost. Herein, we discuss the prospects for long-acting antivirals as prophylaxis of human viral infections other than HIV.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138796864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HTLV European Research Network 2023: the silent pandemic of HTLV-1 infection. HTLV欧洲研究网络2023：HTLV-1感染的无声流行病。

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-10-26 DOI: 10.24875/AIDSRev.M23000064

Carmen de Mendoza, Ana Treviño, Vicente Soriano

引用次数: 0

Mental health crisis in the youth and rebound in sexually transmitted infections. 青少年心理健康危机与性传播感染反弹

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-07-31 DOI: 10.24875/AIDSRev.M23000062

Vicente Soriano, Joaquín González-Cabrera

引用次数: 0

Systematic review and meta-analysis of the global prevalence of sexually transmitted infections in people living with HIV and associated risk factors. 艾滋病毒感染者性传播感染全球流行率及相关风险因素的系统综述和荟萃分析。

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-01-01 DOI: 10.24875/AIDSRev.23000008

Mina Ebrahimi, Nayer Mehdizad, Fatemeh Yeganeh-Sefidan, Hanie Safarpour, Abdol S Pagheh, Amir Pouremamali, Somayeh Shiralizadeh, Ali Ghodrati, Sana Jafari, Firooz Shahrivar, Siamak Heidarzadeh, Mahboobeh Montazeri, Mohammad Yousef-Memar, Sonia M Rodrigues-Oliveira, Maria de-Lourdes-Pereira, Apostolos Beloukas, Kareem Hatam-Nahavandi, Aleksandra Barac, Milad Shirvaliloo, Ehsan Ahmadpour

{"title":"Systematic review and meta-analysis of the global prevalence of sexually transmitted infections in people living with HIV and associated risk factors.","authors":"Mina Ebrahimi, Nayer Mehdizad, Fatemeh Yeganeh-Sefidan, Hanie Safarpour, Abdol S Pagheh, Amir Pouremamali, Somayeh Shiralizadeh, Ali Ghodrati, Sana Jafari, Firooz Shahrivar, Siamak Heidarzadeh, Mahboobeh Montazeri, Mohammad Yousef-Memar, Sonia M Rodrigues-Oliveira, Maria de-Lourdes-Pereira, Apostolos Beloukas, Kareem Hatam-Nahavandi, Aleksandra Barac, Milad Shirvaliloo, Ehsan Ahmadpour","doi":"10.24875/AIDSRev.23000008","DOIUrl":"10.24875/AIDSRev.23000008","url":null,"abstract":"People living with HIV (PLWH) constitute a vulnerable population for acquiring additional sexually transmitted infections (STIs). This study was conducted to provide a summary of the evidence on the global prevalence of STIs in PLWH with an emphasis on infectious agents, diagnostic methods, and related risk factors. PubMed, Scopus, and Web of Science were systematically searched to include records published from January 01, 1990, to January 31, 2022, and the Google Scholar search engine was used to check the search strategy. In total, 132 eligible studies reporting STIs in PLWH were included, enrolling subjects from 35 countries across five continents. The pooled proportion of STIs was estimated to be 30.23% (95% CI, 26.1-34.45%) in PLWH and 20.01% (95% CI, 17.17-23.01%) in HIV-negative patients. Our meta-analysis indicated that in PLWH, the pooled OR of STIs compared to HIV-negatives was 1.77 (95% CI: 1.58-1.98) (p < 0.0001). The pooled OR of STIs by viral infectious agents was highest in PLWH (52.19% [95% CI: 43.88-60.43]) compared with fungal (22.19% [95% CI: 15.64-29.53]), bacterial (19.07% [95% CI: 13.59-26.63]), and parasitic (14.05% [95% CI: 11.88-16.38]) infections. Our findings show that there is a rather significant frequency of STIs among PLWH. This study highlights the need for new programs for the detection, treatment, and prevention of STIs in this at-risk population.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight gain in HIV-infected patients. 艾滋病毒感染者体重增加。

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-01-01 DOI: 10.24875/AIDSRev.M22000057

Antoni Pla Rodríguez, Isabel Serrano Lillo, Cristina Sánchez González, María J Galindo

{"title":"Weight gain in HIV-infected patients.","authors":"Antoni Pla Rodríguez, Isabel Serrano Lillo, Cristina Sánchez González, María J Galindo","doi":"10.24875/AIDSRev.M22000057","DOIUrl":"https://doi.org/10.24875/AIDSRev.M22000057","url":null,"abstract":"Since its emergence, HIV has been linked to metabolic alterations with an impact on the distribution of fat and the weight of people living with HIV. While extreme weight loss and processes such as lipodystrophy were of concern at first, in recent years, and with the appearance of increasingly effective and better tolerated drugs, an abnormal weight gain is paradoxically taking place among people living with HIV. Although this weight gain is a multifactorial process in which lifestyle habits, physical exercise or diet have a great impact, antiretroviral treatment has been recently considered as one of the key causes of this increase according to different clinical trials and real-life cohorts. The use of integrase inhibitors, specifically dolutegravir or bictegravir, and being female and/or from African/American origin appear to contribute to weight gain. In contrast, drugs such as tenofovir disoproxil fumarate would be protective factors. Even though different mechanisms of action have been proposed by which these agents would cause weight gain, the exact processes remain unclarified. Efforts are currently focused on knowing not only these mechanisms, but, more importantly, on finding the clinical relevance that this abnormal weight gain could have in other pathologies such as diabetes or cardiovascular events.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rebound in sexually transmitted infections after the COVID-19 pandemic. 新冠肺炎大流行后性传播感染的反弹。

IF 2.2 4区医学

AIDS reviews Pub Date : 2023-01-01 DOI: 10.24875/AIDSRev.23000015

Vicente Soriano, Hilario Blasco-Fontecilla, Lucía Gallego, José V Fernández-Montero, Carmen de Mendoza, Pablo Barreiro

{"title":"Rebound in sexually transmitted infections after the COVID-19 pandemic.","authors":"Vicente Soriano, Hilario Blasco-Fontecilla, Lucía Gallego, José V Fernández-Montero, Carmen de Mendoza, Pablo Barreiro","doi":"10.24875/AIDSRev.23000015","DOIUrl":"10.24875/AIDSRev.23000015","url":null,"abstract":"Sexually transmitted infections (STIs) have become the second in the global rating of infectious diseases after respiratory infections. Globally, over 1 million, new STI is diagnosed every day. Although four conditions are the most representative and of obligatory declaration (gonorrhea, syphilis, chlamydia, and human immunodeficiency virus [HIV]), there are many other prevalent STI, including trichomona, herpes simplex, papillomavirus, and viral hepatitis. Herein, we perform a narrative and retrospective review, analyzing information from public databases from distinct Spanish government institutions. STI significantly declined in Spain during 2020 as a result of lockdown and social isolation measures dictated in response to the COVID-19 pandemic. After releasing restrictions, a major STI rebound occurred in 2021. Increases were 49% for gonorrhea, 45% for HIV, 39% for chlamydia, and 32% for syphilis. Based on nationwide statistics, we build a narrative review of the recent STI surge after COVID-19. In summary, we propose a holistic approach to confront the current re-emergence of STI. On one hand, new innovative medical advances must be implemented, including new rapid tests, novel vaccines, pre-exposure prophylaxis beyond HIV, and long-acting antivirals. On the other hand, information to citizens needs to be reformulated with interventions aimed to build a healthier society, alike it has been undertaken with tobacco, alcohol, diet, and lifestyle. STI determines important sexual, reproductive, and maternal-child health consequences. To promote human well-being or flourishing, the education of adolescents and young adults should be aligned with human ecology. Therefore, it is urgent to address new approaches in sexual health that represent a clear benefit for individual persons and society. In this way, favoring a cultural evolution aimed to delay the age of first sexual intercourse and the avoidance of multiple sex partners should be prioritized.","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1